Showing results (591-600 of 3,280) with videos related to

Sort By:
Pageof 328
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|March 28, 2014
[Gaucher's disease and imiglucerase in 2009/2010: what leads to a suddenly enforced prioritisation?]K Hofstetter, H Raspe, S Stumpf, et al.
Fortschritte Der Medizin|April 14, 1983
[Destruction of ureteral tumors with the neodymium-YAG laser. A new, organ-preserving surgical procedure]A Hofstetter, R Böwering, E Keiditsch, et al.
The New England Journal of Medicine|January 9, 1986
Increased 24-hour energy expenditure in cigarette smokersA Hofstetter, Y Schutz, E Jéquier, et al.
The Journal of Organic Chemistry|October 25, 2001
NMR Structure Determination of Ion Pairs Derived from Quinine: A Model for Templating in Asymmetric Phase-Transfer Reductions by BH(4)(-) with Implications for Rational Design of Phase-Transfer CatalystsChristine Hofstetter, Patricia Stone Wilkinson, Thomas C. Pochapsky
MMW Fortschritte Der Medizin|June 26, 2003
[Papules, fungi, protozoa--or cancer? Many skin conditions of the penis can be confirmed with biopsy]P Schneede, D Frimberger, E Hungerhuber, et al.
World Neurosurgery|April 2, 2022
Innovations in Spinal EndoscopyIbrahim Hussain, Christoph P Hofstetter, Michael Y Wang
Neuroscience Letters|October 4, 2005
Permanent effector phenotype of neuroantigen-specific T cells acquired in the central nervous system during experimental allergic encephalomyelitisHarald H Hofstetter, Klaus V Toyka, Ralf Gold
The Journal of Comparative Neurology|March 1, 2005
RhoA, RhoB, RhoC, Rac1, Cdc42, and Tc10 mRNA levels in spinal cord, sensory ganglia, and corticospinal tract neurons and long-lasting specific changes following spinal cord injuryMatthias K Erschbamer, Christoph P Hofstetter, Lars Olson
Experimental Neurology|May 19, 2005
A spinal cord pathway connecting primary afferents to the segmental sympathetic outflow systemC P Hofstetter, J P Card, L Olson
Der Urologe. Ausg. A|March 1, 1997
[Immunotherapy of metastatic renal cell carcinoma. Is clinical use justified in view of outcome, side effects and costs?]R Oberneder, M Kriegmair, M Staehler, et al.
Pageof 328